Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker

Out of Ignorance7.54K FollowersFollow5ShareSavePlay(13min)CommentsSummaryAcadia Pharmaceuticals' two approved drugs, NUPLAZID and DAYBUE, are guided to continue their strong growth trajectories.These two drugs alone support a "buy" thesis for Acadia.Learning from previously rejected drugs adds to the value of its strong late-stage pipeline.Solid liquidity and cash flow generation with no debt support Acadia's value proposition. mohd izzuan/iStock via Getty Images I have followed and chronicled the ups and downs of ACADIA Pharmaceuticals (ACAD) since 07/2017's "Acadia: Order For Central Nervous Systems In Need". My most recent Acadia article focusing exclusively on Acadia was 10/2022's "Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah" ("This article was written byOut of Ignorance7.54K FollowersFollowWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences.Analyst’s Disclosure: I/we have a beneficial long position in the shares of ACAD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I may buy additional interests in Acadia over the next 72 hours.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.